Funding/investment

AstraZeneca’s potential $1.5B insitro deal puts AI on the hardest question in cardiometabolic R&D
AstraZeneca has partnered with AI therapeutics company insitro to discover new targets and medicines for MASH and cardiomyopathies, paying $40 million upfront with up to $1.46 billion tied to future development and commercial milestones.

Preparedness Finally Has Capital

Roche’s Nearly $2B Atavistik Bet Goes After Cardiometabolic Targets Other Drugs Struggle to Reach

Novo’s €1.165B Bet Targets the Burden of Weekly Injections

Novo’s $1.4B Orbis Deal Bets on a New Route to Oral Cardiometabolic Drugs

Three drugs, three biological hypotheses: Kardigan is putting precision cardiology to the test

Obesity drugs may move beyond appetite suppression. Moonwalk just raised $70 million to target fat tissue directly

Beyond GLP-1s: Lilly is spending billions on a more targeted future in neuroscience

Oral GLP-1 drugs could widen access, but high prices may do the opposite

The Novo Nordisk Foundation is going global on cardiometabolic disease.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
